Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification.

benzodiazepine detoxifcation flumazenil high dose withdrawal

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2021
Historique:
received: 24 12 2020
accepted: 15 02 2021
entrez: 5 4 2021
pubmed: 6 4 2021
medline: 6 4 2021
Statut: epublish

Résumé

An effective approach in the treatment of benzodiazepine (BZD) overdosing and detoxification is flumazenil (FLU). Studies in chronic users who discontinued BZD in a clinical setting suggested that multiple slow bolus infusions of FLU reduce BZD withdrawal symptoms. The aim of this study was to confirm FLU efficacy for reducing BZD withdrawal syndrome by means of continuous elastomeric infusion, correlated to drugs plasma level and patients' compliance.

Identifiants

pubmed: 33815177
doi: 10.3389/fpsyt.2021.646038
pmc: PMC8012511
doi:

Types de publication

Journal Article

Langues

eng

Pagination

646038

Informations de copyright

Copyright © 2021 Benini, Gottardo, Chiamulera, Bertoldi, Zamboni and Lugoboni.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int Clin Psychopharmacol. 2007 Sep;22(5):292-8
pubmed: 17690598
Drug Saf. 1997 Sep;17(3):181-96
pubmed: 9306053
Intern Emerg Med. 2019 Nov;14(8):1271-1278
pubmed: 31076977
J Psychopharmacol. 2013 Feb;27(2):222-7
pubmed: 22596209
J Antimicrob Chemother. 2016 May;71(5):1402-7
pubmed: 26832749
Eur J Pharmacol. 2014 Jun 15;733:1-6
pubmed: 24704372
Psychopharmacology (Berl). 1999 Nov;147(2):200-9
pubmed: 10591888
Drug Alcohol Depend. 2014 Sep 1;142:105-9
pubmed: 25001277
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005194
pubmed: 16856084
Expert Opin Drug Saf. 2018 May;17(5):451-456
pubmed: 29621907
N Engl J Med. 2017 Jun 15;376(24):2399-2400
pubmed: 28614686
Br J Clin Pharmacol. 2014 Feb;77(2):285-94
pubmed: 23126253
Br J Clin Pharmacol. 1986 Oct;22(4):421-8
pubmed: 3094572
J Psychopharmacol. 2014 Jul;28(7):703-6
pubmed: 24554692
Front Neurosci. 2020 Jul 21;14:747
pubmed: 32848544
Psychopharmacologia. 1961 Feb 20;2:63-8
pubmed: 13715373
Clin Pharmacokinet. 1988 Jan;14(1):1-12
pubmed: 3127102
Acta Pharm Nord. 1990;2(2):101-4
pubmed: 2112941
Acta Anaesthesiol Scand Suppl. 1995;108:3-14
pubmed: 8693922
Int J Environ Res Public Health. 2017 Jan 04;14(1):
pubmed: 28054975
Psychopharmacology (Berl). 1997 May;131(2):153-60
pubmed: 9201803
Front Psychiatry. 2020 Nov 04;11:601827
pubmed: 33329156
Psychopharmacology (Berl). 2005 Mar;178(2-3):259-67
pubmed: 15452683
Eur J Clin Pharmacol. 1996;50(1-2):19-25
pubmed: 8739806
CNS Drugs. 2009;23(1):19-34
pubmed: 19062773
J Clin Psychiatry. 2002 Sep;63(9):817-25
pubmed: 12363124
Acta Psychiatr Scand. 1998 Feb;97(2):153-6
pubmed: 9517911
Addiction. 2011 Dec;106(12):2086-109
pubmed: 21714826
Addict Biol. 2002 Oct;7(4):385-95
pubmed: 14578014
Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):37-44
pubmed: 26096314
J Psychopharmacol. 2016 Oct;30(10):1047-53
pubmed: 27166362
Eur J Pharmacol. 2005 Jan 10;507(1-3):7-13
pubmed: 15659288
J Psychopharmacol. 2021 Mar;35(3):211-220
pubmed: 33426982

Auteurs

Anna Benini (A)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Rossella Gottardo (R)

Forensic Toxicology Laboratory, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Cristiano Chiamulera (C)

Department of Diagnostics and Public Health, University of Verona, Verona, Italy.

Anna Bertoldi (A)

Department of Internal Medicine, Addiction Unit, Verona University Hospital, Verona, Italy.

Lorenzo Zamboni (L)

Department of Internal Medicine, Addiction Unit, Verona University Hospital, Verona, Italy.

Fabio Lugoboni (F)

Department of Internal Medicine, Addiction Unit, Verona University Hospital, Verona, Italy.

Classifications MeSH